MedTrace Logo

Short-Term Rhodiola Rosea for Anaerobic Performance and Cognitive Function in Resistance-Trained Adults

NCT07225413 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 27

Last updated 2025-11-06

No results posted yet for this study

Summary

This study will evaluate whether 7 days of Rhodiola rosea (golden root) supplementation can improve resistance-exercise performance and cognitive function in resistance-trained men and women. Participants will complete four 7-day periods in a randomized, double-blind, crossover order: (1) no-capsule control, (2) placebo, (3) low-dose Rhodiola rosea, and (4) high-dose Rhodiola rosea. On day 7 of each period, they will report to the laboratory for performance testing that includes bench press and leg press 1-repetition maximum (1RM), a third set to failure at 60% 1RM, Tendo-derived mean and peak power, a 30-second Wingate test, and the paper-and-pencil Stroop Color-Word Test for executive function. Secondary outcomes include ratings of perceived exertion, readiness to perform (visual analog scale), and heart rate and blood pressure measured at rest and 1 minute after exercise. The central hypothesis is that short-term Rhodiola rosea, compared with control and placebo, will produce small but measurable improvements in strength, set-to-failure volume, and Stroop performance, with minimal changes in hemodynamics.

Conditions

  • Healthy Volunteers

Interventions

DIETARY_SUPPLEMENT

Rhodiola rosea (low dose)

Participants will ingest a low-dose Rhodiola rosea extract (≈approximately 200 mg/day) once daily for 7 consecutive days. On day 7, \~60 minutes after the final dose, they will complete the exercise and cognitive testing battery (bench press, leg press, set to failure at 60% 1RM, Tendo power, 30-s Wingate, Stroop test, HR/BP, RPE). This intervention is used to determine whether short-term, lower-dose RR improves resistance performance and executive function compared with placebo and control.

DIETARY_SUPPLEMENT

Rhodiola rosea (high dose)

Participants will ingest a high-dose Rhodiola rosea extract (≈approximately 1,500 mg/day) once daily for 7 consecutive days. On day 7, \~60 minutes after the final dose, they will complete the same performance and cognitive testing battery. This arm allows dose-response comparison with the low-dose RR, placebo, and no-capsule control conditions.

DIETARY_SUPPLEMENT

Placebo capsules

Participants will ingest matching placebo capsules once daily for 7 days. On day 7, \~60 minutes after capsule ingestion, they will complete the full testing battery. This intervention controls for expectancy, capsule handling, and timing.

Sponsors & Collaborators

  • Jacksonville State University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Weeks
Max Age
40 Weeks
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-02-01
Primary Completion
2022-10-17
Completion
2022-12-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07225413 on ClinicalTrials.gov